ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
33 announcements with these filters
Record Q2 FY27 revenue of about ₹376 Cr (+28% QoQ), but gross margin fell 4ppt to 49% on West Asia raw-material costs. Management gave no numerical forward guidance; margin recovery depends on price hikes from Q3.
Blue Jet Healthcare filed CARE Ratings' monitoring agency report for the QIP proceeds for the quarter ended 30 September 2026. The report shows nil deviation from the offer objects on the ₹800 crore issue.
Q2 FY27 revenue Rs3,757mn (record, +127% YoY), EBITDA Rs1,188mn (31.6%), PAT Rs1,025mn (27.3%). H1 FY27 revenue Rs6,689mn, PAT Rs1,808mn. Growth led by pharma intermediates and API.
Blue Jet Healthcare reported standalone financial results for the quarter ended September 30, 2026. Revenue from operations reached Rs.375.74 Crore with a net profit of Rs.102.52 Crore.
Blue Jet Healthcare scheduled a board meeting on November 5, 2026, to consider Q1 FY27 unaudited results. No financial figures are disclosed.
Blue Jet Healthcare Limited filed its quarterly shareholding pattern for the period ended 30 September 2026 under Regulation 31(1)(b). Promoter and promoter group hold about 73.15% of the equity.
Blue Jet Healthcare Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026, as required by regulatory norms.
Blue Jet Healthcare held its 58th AGM, approving audited financials, a Re 1.20 dividend, and director re-appointments. No material amendments were noted.
Blue Jet Healthcare Limited has released its Annual Report for FY 2025-26. The 58th Annual General Meeting is scheduled for September 21, 2026, via video conferencing.
Blue Jet Healthcare Limited has released its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26. The report details the company's ESG performance and statutory disclosures.
Blue Jet Healthcare Limited will hold its 58th Annual General Meeting on September 21, 2026. The agenda includes a final dividend recommendation of ₹1.20 per share.
Blue Jet Healthcare reported Q1 FY27 revenue of INR 293 crores (+25% QoQ) and EBITDA of INR 98 crores. Management highlighted a shift toward higher-value PI and API verticals alongside significant upcoming capex.
Blue Jet Healthcare reported Q1 FY27 revenue of ₹2,931mn, up 25% QoQ but down 17% YoY. Management is focusing on capacity expansion and forward integration into advanced contrast media intermediates.
Blue Jet Healthcare reported Q1 FY27 Revenue of ₹2,931mn, up 25% QoQ but down 17.4% YoY. Strategy focuses on expanding R&D and CDMO adjacencies.
Blue Jet Healthcare announced the re-appointment of executive directors Shiven Akshay Arora and Akshay Bansarilal Arora, and statutory auditor KKC & Associates LLP.
Blue Jet Healthcare Ltd reported revenue from operations of ₹293.1 Cr (-17.4% YoY) and net profit of ₹78.3 Cr (-14.1% YoY) for Q1 FY27.
Blue Jet Healthcare Limited has scheduled a board meeting on August 3, 2026. The board will consider unaudited standalone financial results for the June quarter.
Blue Jet Healthcare received a Silver Medal from EcoVadis for sustainability excellence. The company now ranks among the top 15% of companies globally.
Blue Jet Healthcare successfully closed its QIP, raising approximately ₹800 Crore. The company allocated 1.58 crore shares at ₹506 per share to institutional investors.
Blue Jet Healthcare approved a QIP with a floor price of ₹531.70 per share. The fund raise is subject to shareholder and regulatory compliance.
Blue Jet Healthcare submitted its audited standalone financial statements for FY 2026, approved by the board. The documents are now on the company's website.
Blue Jet Healthcare Limited disclosed its shareholding pattern as of 30 June 2026, showing promoter holdings and public shareholding below 25%. The filing complies with Regulation 31(1)(b).
Blue Jet Healthcare responded to an exchange query on unusual volume movement. The company stated all disclosures are timely and the volume is market-driven.
Blue Jet Healthcare reported FY26 revenue of ₹947cr (-8% YoY) and PAT margin of 26%. Management highlights transition from investment to commercialization phase via significant Vizag greenfield expansion.
Blue Jet Healthcare submitted its Annual Secretarial Compliance Report for FY2026. The auditor reported nil non-compliances, confirming the company's adherence to SEBI governance regulations.
Blue Jet Healthcare scheduled an EGM for June 17, 2026, to approve a fund raise. Shareholders will consider issuing equity shares or other securities via special resolution.
Blue Jet Healthcare Limited convened an EGM for June 17, 2026, to approve a ₹1000.00 Crore fundraise. The capital will support expansion, debt repayment, and general corporate purposes.
Blue Jet Healthcare reported FY26 revenue of ₹9,473 mn with 31% EBITDA margin. Strong growth in Contrast Media was offset by declines in Pharma Intermediates & API due to customer inventory normalization.
Blue Jet Healthcare recommended a final dividend of ₹0.6 per share for FY2025-26. The record date and general meeting details will be announced later.
Blue Jet Healthcare re-appointed M/s. H.H. Chimthanawala & Co as Internal Auditors for a 12-month term. The appointment remains effective from April 1, 2026, ensuring continued audit oversight.